DAX24.233 +0,1%Est505.673 +0,1%MSCI World4.343 -0,1%Top 10 Crypto15,26 +0,4%Nas22.942 +0,9%Bitcoin95.887 +1,2%Euro1,1614 ±-0,0%Öl65,83 -0,2%Gold4.069 -1,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Beyond Meat A2N7XQ TKMS thyssenkrupp Marine Systems TKMS00 Rheinmetall 703000 NVIDIA 918422 RENK RENK73 D-Wave Quantum A3DSV9 SAP 716460 DroneShield A2DMAA Tesla A1CX3T Deutsche Telekom 555750 Infineon 623100 Siemens Energy ENER6Y Plug Power A1JA81 Volkswagen (VW) vz. 766403 Lufthansa 823212
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Hoffnung auf Entspannung im Handelsstreit: DAX unentschlossen -- Asiens Börsen fest -- Intel: Starke Zahlen -- HENSOLDT: Höhere Ziele -- DroneShield, SuperMicro, TKMS, Beyond Meat, Dow im Fokus
Top News
Aktien-Analyse: UBS AG bewertet Beiersdorf-Aktie Aktien-Analyse: UBS AG bewertet Beiersdorf-Aktie
UBS AG: Buy für RWE-Aktie UBS AG: Buy für RWE-Aktie
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
ZERO WINTERDEAL 2025: Bis zu 300 € Prämie + Gratis-Aktie + finanzen.net MSCI World-ETF - Jetzt informieren!

AcelRx Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
0,9650 EUR -0,0330 EUR -3,31 %
FSE
1,15 USD -0,03 USD -2,54 %
BTT
AcelRx Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.46,33 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DWPN

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00444T2096

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTLPH

AcelRx Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireTalphera Announces the Appointment of Joe Todisco to Board of Directors
PR NewswireTalphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
PR NewswireTalphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial
Wer­bungAcelRx Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireTalphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireTalphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025
PR NewswireTalphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025
PR NewswireTalphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
PR NewswireTalphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
PR NewswireTalphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
PR NewswireTalphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
PR NewswireAscentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
PR NewswireTalphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireTalphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
PR NewswireTalphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
PR NewswireTalphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireTalphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
PR NewswireTalphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireTalphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024
PR NewswireTalphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireTalphera to Participate at A.G.P. Virtual Healthcare Conference
PR NewswireTalphera Announces First Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireTalphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
PR NewswireTalphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
PR NewswireTalphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
PR NewswireTalphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024
PR NewswireTalphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
PR NewswireAcelRx Announces Rebranding With Name Change to Talphera, Inc.
PR NewswireAcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
PR NewswireAcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PR NewswireAcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study
PR NewswireAcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
PR NewswireAcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
PR NewswireAcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
PR NewswireAcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
PR NewswireAcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
PR NewswireAcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
PR NewswireAcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
PR NewswireAcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
PR NewswireAcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023

AcelRx Pharmaceuticals News

AcelRx Pharmaceuticals News: auf dieser Seite finden Sie alle AcelRx Pharmaceuticals News und Nachrichten zur AcelRx Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AcelRx Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AcelRx Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.